Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at - X-COM - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2017-10-03 19:39:52		Visterra Awarded CARB-X Contract to Advance Development of VIS705 – VIS705 is Visterra’s Novel Antibody-Drug Conjugate Candidate for the Treatment of Deadly Pseudomonas Bacterial Infections – – Contract Valued at Add to Reading List Source URL: visterrainc.com Download Document from Source Website File Size: 113,31 KB Share Document on Facebook